Targovax

Targovax is a Norwegian biotech company within immuno-oncology.[1][2] The company is listed on Oslo Stock Exchange.[3] Targovax merged with Oncos Therapeutics, a Finnish immuno-oncology biotech company, in 2015.[4]

The company has two approaches for treatment-resistant solid tumors - a peptide-based immunotherapy platform for patients with RAS-mutated cancers, and an adenovirus cancer therapy based on technology from Oncos Therapeutics.[5]

Product pipeline

TG01, a peptide-based targeted immunotherapy, is a peptide vaccine against cancers with RAS mutations. The vaccine is currently in a phase I/II trial in pancreatic cancer.[6][7]

ONCOS-102, an oncolytic virus therapy, is a human serotype 5 adenovirus engineered to induce systemic anti-tumor T cell response in cancer patients,[8] It targets GM-CSF.[9]

Both TG01 (pancreatic cancer) and ONCOS-102 (mesothelioma, ovarian cancer, soft tissue sarcoma) have Orphan Drug Designation with the FDA and EMA.[10]

References

  1. ↑ "Can Oncolytic Viruses be the key to Treat Resistant Tumors?". Labiotech.eu. 2016-11-18. Retrieved 2017-04-05.
  2. ↑ "Targovax | crunchbase". www.crunchbase.com. Retrieved 2017-04-05.
  3. ↑ ASA, Targovax. "Targovax ASA moves share listing to Oslo Børs". GlobeNewswire News Room. Retrieved 2017-04-05.
  4. ↑ "Targovax to merge with Oncos then IPO in push for immuno-oncology mainstream | FierceBiotech". www.fiercebiotech.com. Retrieved 2017-04-05.
  5. ↑ "Can Oncolytic Viruses be the key to Treat Resistant Tumors?". Labiotech.eu. 2016-11-18. Retrieved 2017-04-05.
  6. ↑ "Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2017-04-05.
  7. ↑ "Targovax climbs after posting survival data from I-O trial | FierceBiotech". www.fiercebiotech.com. Retrieved 2017-04-05.
  8. ↑ "ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2017-04-05.
  9. ↑ Targovax recruits the first patient in a trial with the oncolytic virus ONCOS-102 in malignant pleural mesothelioma
  10. ↑ "Oncos Therapeutics granted US and EU Orphan Drug Designation for ONCOS-102 in ovarian cancer". News Powered by Cision. Retrieved 2017-04-05.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.